Abstract 23P
Background
Breast cancer is the second most common cancer in women worldwide and contributes to a significant amount of mortality annually. It also contributes significantly to cancer-related morbidity in Bali especially in Gianyar district where most of the breast cancers are diagnosed at an advanced stage. Therefore, we aimed to evaluate the correlation between the levels of knowledge with the attitude of local-productive age women toward SADARI (breast self-assessment).
Methods
A family-based cross-sectional study was conducted in August 2018 in the Pejeng Kaja village, Ubud, Bali. The level of knowledge such as the definition of breast cancer, risk factors, therapy, prevention and several aspects of SADARI method was examined using a validated questionnaire. All of the data were subsequently recorded into SPSS for analysis.
Results
122 respondents were enrolled in this study with a mean age of 45.65±9.51 years. More than half of the respondents were having at least high school education and 55% know breast cancer. However, 46.7% were known about SADARI. 5 variables were significantly associated with the status of SADARI knowledge namely: level of education, knowledge about breast cancer, breast cancer prevention, and how to perform SADARI as well as the frequency of SADARI performance by respondents (p < 0.05). Risk assessment for each variable showed that all variables had OR > 5 with the biggest OR on the level of education (OR: 7.2; 95%CI: 3.56-14.75).
Conclusions
We conclude that the level of education, knowledge about breast cancer, early symptoms of breast cancer, breast cancer prevention, and how to perform SADARI as well as frequency of SADARI performance influenced the performance rate of SADARI in reproductive women in Pejeng Kaja with low level of education posed the greatest risk of not performing SADARI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract